Metraipolis › archive › dc_06d763ce44cd

Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis… — Europe PMC PMID:40063867

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40063867
DOI: 10.1371/journal.pntd.0012851
License (as archived): CC0-1.0
Archived: 2026-10-06T13:17:19.965Z
SHA-256 of the archived text: b7bbf1f19b2142b07a2d397bbcbd40d03844068d224879e3c5b13a7ef9738be4
Stable URL of this page: https://metraipolis.com/documento/dc_06d763ce44cd

How to cite

Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis… — Europe PMC PMID:40063867 — Europe PMC (en), https://europepmc.org/article/MED/40063867 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_06d763ce44cd (Metraipolis archive dc_06d763ce44cd, sha256 b7bbf1f19b2142b07a2d397bbcbd40d03844068d224879e3c5b13a7ef9738be4)

BibTeX

@misc{dc06d763ce44cd,
  title = {Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis… — Europe PMC PMID:40063867},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40063867},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_06d763ce44cd; sha256 b7bbf1f19b2142b07a2d397bbcbd40d03844068d224879e3c5b13a7ef9738be4},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40063867. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). We compared the effectiveness of a single round of MDA with IDA or DA on hookworm and strongyloidiasis in PNG. Methodology/principal findings: This study was conducted as part of a cluster randomized trial of MDA with IDA versus DA for LF in individuals willing to provide stool and blood samples at baseline and 12 months after MDA. Participants from 23 villages were included in the clinical trial. Primary outcomes were changes in hookworm prevalence and infection intensity assessed by Kato Katz and Strongyloides prevalence by serology. Hookworm prevalence at baseline was 78% (91/117) and 80% (119/149) in villages assigned to DA and IDA treatment, respectively. Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (p 2000 egg per gram (EPG)) similarly decreased from 8.7% to 1.5% after DA (p = 0.001) and from 5.7% to 1.0% after IDA (p = 0.002). Using a logistic regression model adjusting for age, gender, baseline hookworm prevalence, and village drug coverage, IDA resulted in a 45% greater reduction in hookworm prevalence than DA (Odds ratio 0.55, 95% CI [0.31,0.99], p = 0.049). MDA also reduced hookworm transmission. Strongyloides seroprevalence at baseline was 68% (192/283) and 62% (180/290) in IDA and DA villages, respectively, with 49% becoming seronegative in the IDA versus 23% in DA villages at 12 months (p = 0.0001). Conclusions/significance: MDA with IDA was more effective than DA for reducing hookworm and Strongyloides infections in PNG, extending the benefit of MDA with IDA beyond its effect on LF.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS neglected tropical diseases, 2025 (prima pubblicazione 2025-03-10).
Identificativi: PMID 40063867 · PMCID PMC11893124 · DOI 10.1371/journal.pntd.0012851.
Descrittori MeSH principali: Strongyloidiasis; Elephantiasis, Filarial; Hookworm Infections; Ivermectin; Anthelmintics; Mass Drug Administration.
Pagina: https://europepmc.org/article/MED/40063867 — https://doi.org/10.1371/journal.pntd.0012851. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T11:32:36.059Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.